Radium Ra 223 dichloride
- Generic Name
- Radium Ra 223 dichloride
- Brand Names
- Xofigo
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2Ra
- CAS Number
- 444811-40-9
- Unique Ingredient Identifier
- RJ00KV3VTG
- Background
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is cur...
- Indication
Used in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant.
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 48
- Registration Number
- NCT04489719
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸University of Wisconsin-Madison, Madison, Wisconsin, United States
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: Enzalutamide Oral CapsuleDrug: Niraparib plus Abiraterone acetate plus PrednisoneDrug: Capivasertib plus DocetaxelDrug: CarboplatinDrug: Abiraterone Oral TabletDrug: Cabazitaxel 60 mg Solution for InjectionDrug: ApalutamideDrug: DarolutamideDrug: Docetaxel Injectable SolutionDrug: Radium Chloride Ra-223
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 750
- Registration Number
- NCT03903835
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇧🇪OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪AZ Groeninge, Kortrijk, Belgium
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 402
- Registration Number
- NCT03458559
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Netherlands
The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.
- Conditions
- Interventions
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2019-06-11
- Target Recruit Count
- 21
- Registration Number
- NCT03368989
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 20
- Registration Number
- NCT03304418
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223
- Conditions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT03223597
- Locations
- 🇳🇱
The Netherlands Cancer Intitute, Amsterdam, Netherlands
🇳🇱Rijnstate, Arnhem, Netherlands
🇳🇱Meander Medical Center, Amersfoort, Utrecht, Netherlands
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-09-21
- Lead Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT03062254
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Quebec, Canada
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 40
- Registration Number
- NCT02903160
- Locations
- 🇺🇸
Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02814669
- Locations
- 🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)
- Conditions
- Interventions
- First Posted Date
- 2015-06-29
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- University Hospital Freiburg
- Target Recruit Count
- 274
- Registration Number
- NCT02484339
- Locations
- 🇩🇪
Klinikum der Universität München, München, Germany
🇩🇪Universitätsklinikum Würzburg, Würzburg, Germany
🇩🇪Universitätsklinikum "Carl Gustav Carus" der Technischen Universität Dresden, Dresden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.